These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35875545)

  • 1. A Preliminary
    Liu L; Zhang X; Kayastha S; Tan L; Zhang H; Tan J; Li L; Mao J; Sun Y
    Front Microbiol; 2022; 13():825745. PubMed ID: 35875545
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
    Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gao L; Xia X; Gong X; Zhang H; Sun Y
    Front Cell Infect Microbiol; 2024; 14():1296151. PubMed ID: 38304196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interactions between 17-AAG and azoles against Exophiala dermatitidis.
    Gao L; Sun Y; He C; Li M; Zeng T
    Mycoses; 2018 Nov; 61(11):853-856. PubMed ID: 29998564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
    Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
    J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazole Evolution of Candida parapsilosis Results in Cross-Resistance to Other Antifungal Drugs, Influences Stress Responses, and Alters Virulence in an Antifungal Drug-Dependent Manner.
    Papp C; Bohner F; Kocsis K; Varga M; Szekeres A; Bodai L; Willis JR; Gabaldón T; Tóth R; Nosanchuk JD; Vágvölgyi C; Gácser A
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33115837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Analysis of
    Kim SH; Iyer KR; Pardeshi L; Muñoz JF; Robbins N; Cuomo CA; Wong KH; Cowen LE
    mBio; 2019 Jan; 10(1):. PubMed ID: 30696744
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring synergy between azole antifungal drugs and statins for Candida auris.
    Halliday C; Kim HY; Tay E; Chen SCA; Alffenaar JW
    J Antimicrob Chemother; 2023 Dec; 78(12):2824-2829. PubMed ID: 37823357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.
    Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY
    Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris.
    Eldesouky HE; Li X; Abutaleb NS; Mohammad H; Seleem MN
    Int J Antimicrob Agents; 2018 Dec; 52(6):754-761. PubMed ID: 30145250
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Gao L; Sun Y; Yuan M; Li M; Zeng T
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253207
    [No Abstract]   [Full Text] [Related]  

  • 13. Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant
    Tan J; Jiang S; Tan L; Shi H; Yang L; Sun Y; Wang X
    Front Microbiol; 2021; 12():649026. PubMed ID: 34054751
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azole resistance in Candida spp. isolated from Catú Lake, Ceará, Brazil: an efflux-pump-mediated mechanism.
    Brilhante RS; Paiva MA; Sampaio CM; Castelo-Branco DS; Teixeira CE; de Alencar LP; Bandeira TJ; Monteiro AJ; Cordeiro RA; Pereira-Neto WA; Sidrim JJ; Moreira JL; Rocha MF
    Braz J Microbiol; 2016; 47(1):33-8. PubMed ID: 26887224
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sun Y; Gao L; Yuan M; Yuan L; Yang J; Zeng T
    Front Cell Infect Microbiol; 2020; 10():576975. PubMed ID: 33194816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.
    Mahmoud DE; Faraag AHI; Abu El-Wafa WM
    World J Microbiol Biotechnol; 2021 Oct; 37(11):191. PubMed ID: 34632522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.